ProBioGen receives undisclosed milestone payment from Merus on use of GlymaxX ADCC enhancement technology in MCLA129

ProBioGen receives undisclosed milestone payment from Merus on use of GlymaxX ADCC enhancement technology in MCLA─129

ProBioGen AG, a premier service & technology provider for complex therapeutic antibodies and glycoproteins, announced that the company achieved an undisclosed milestone payment from Merus N.V based on Merus'

More From BioPortfolio on "ProBioGen receives undisclosed milestone payment from Merus on use of GlymaxX ADCC enhancement technology in MCLA─129"